Antibiotic Resistance of Non-pneumococcal Streptococci and Its Clinical Impact

Chapter
First Online:

Abstract

The taxonomy of streptococci has undergone major changes during the last two decades. The present classification is based on both phenotypic and genotypic data. Phylogenetic classification of streptococci is based on 16S rRNA sequences [1], and it forms the backbone of the overall classification system of streptococci. Phenotypic properties are also important, especially for clinical microbiologists. The type of hemolysis on blood agar, reaction with Lancefield grouping antisera, resistance to optochin, and bile solubility remain important for grouping of clinical Streptococcus isolates and therefore treatment options [2]. In the following chapter, two phenotypic classification groups, viridans group streptococci (VGS) and beta-hemolytic streptococci, will be discussed.

Keywords

Non-pneumococcal Viridans Beta-hemolytic Streptococcus Antibiotic Resistance Neutropenic Endocarditis 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Kawamura Y, Hou XG, Sultana F, Miura H, Ezaki T. Determination of 16S rRNA sequences of Streptococcus mitis and Streptococcus gordonii and phylogenetic relationships among members of the genus Streptococcus. Int J Syst Bacteriol. 1995;45:406–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Johnson CC, Tunkel AR. Viridans Streptococci and Groups C and G Streptococci. In: Mandell GB, Bennett J, Dolin R, editors. Princiles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2000. p. 2167–73.Google Scholar
  3. 3.
    Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5(1):4–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Doern CD, Burnham CA. It’s not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations. J Clin Microbiol. 2010;48(11):3829–35.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Whiley RA, Beighton D. Current classification of the oral streptococci. Oral Microbiol Immunol. 1998;13:195–216.PubMedCrossRefGoogle Scholar
  6. 6.
    Lancefield RC. A serological differentiation of human and other groups of hemolytic streptococci. J Exp Med. 1933;57:571–95.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Bisno AL, van de Rijn I. Classification of streptococci. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone Inc.; 1995. p. 1784–5.Google Scholar
  8. 8.
    Farley TA, Wilson SA, Mahoney F, Kelso KY, Johnson DR, Kaplan EL. Direct inoculation of food as the cause of an outbreak of group A streptococcal pharyngitis. J Infect Dis. 1993;167:1232–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Khan Z, et al. Group A Streptococcal infections. Medscape. http://emedicine.medscape.com/article/228936-overview. Accessed 14 Sept 2014.
  10. 10.
    Donald FE, Slack RCB, Colman G. Streptococcus pyogenes vulvovaginitis in children in Nottingham. Epidemiol Infect. 1991;106:459–65.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996;334:240–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Orden B, Martin R, Franco A, Ibañez G, Mendez E. Balanitis caused by group A beta-hemolytic streptococci. Pediatr Infect Dis J. 1996;15:920–1.PubMedCrossRefGoogle Scholar
  13. 13.
    Bisno AL. Streptococcus pyogenes. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone Inc.; 1995. p. 1786–99.Google Scholar
  14. 14.
    Stollerman GH. Variation in group A streptococci and the prevalence of rheumatic fever: a half-century vigil. Ann Intern Med. 1993;118:467–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Weinstein L, Le Frock J. Does antimicrobial therapy of streptococcal pharyngitis or pyoderma alter the risk of glomerulonephritis? J Infect Dis. 1971;124:229–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol. 1962;89:307–13.PubMedGoogle Scholar
  17. 17.
    Griffith MB. The serological classification of Streptococcus pyogenes. J Hygiene. 1934;34:542–84.CrossRefGoogle Scholar
  18. 18.
    Maxted WR, Widdowson JP, Fraser CAM, Ball LC, Bassett DCJ. The use of the serum opacity reaction in the typing of group-A streptococci. J Med Microbiol. 1973;6:83–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Poyart C, Quesne G, Couloun S, Berche P, Trieu-Cuot P. Identification of streptococci to species level by sequencing the gene encoding the manganese-dependent superoxide dismutase. J Clin Microbiol. 1998;36:41–7.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Edwards MS, Baker CJ. Streptococcus agalactiae (group B streptococcus). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995. p. 1835–45.Google Scholar
  21. 21.
    Woods CJ. Steptococcus Group B infections. Medscape. http://emedicine.medscape.com/article/229091-overview. Accessed 14 Sept 2014.
  22. 22.
    Wessels MR. Group C and group G streptococcal infection. In: Post TW, editor. UpToDate. Waltham, MA: UpToDate. Accessed 14 Sept 2014.Google Scholar
  23. 23.
    Walsh C. Antibiotics: actions, origins, resistance. Washington, DC: ASM Press; 2003.CrossRefGoogle Scholar
  24. 24.
    Chambers HF. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J Infect Dis. 1999;179:S353–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Ajdic D, McShan WM, McLaughlin RE, Saviæ G, Chang J, Carson MB, Primeaux C, Tian R, Kenton S, Jia H, Lin S, Qian Y, Li S, Zhu H, Najar F, Lai H, White J, Roe BA, Ferretti JJ. Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc Natl Acad Sci U S A. 2002;99:14434–9.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Hoskins J, Alborn WEJ, Arnold J, Blaszczak LB, Burgett S, DeHoff BS, Estrem ST, Fritz L, Fu D-J, Fuller W, Geringer C, Gilmour R, Glass JS, Khoja H, Kraft AR, Lagace RE, LeBlanc DJ, Lee LN, Lefkowitz EJ, Lu J, Matsushima P, McAhren SM, McHenney M, McLeaster K, Mundy CW, Nicas TI, Norris FH, O’Gara M, Peery RB, Robertson GT, Rockey P, Sun P-M, Winkler ME, Yang Y, Young-Bellido M, Zhao G, Zook CA, Baltz RH, Jaskunas SR. Genome of the bacterium Streptococcus pneumoniae Strain R6. J Bacteriol. 2001;183:5709–17.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Dowson CG, Hutchison A, Woodford N, Johnson AP, George RC, Spratt BG. Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of Streptococcus pneumoniae. Proc Natl Acad Sci U S A. 1990;87:5858–62.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Ergin A, Ercis S, Hascelik G. In vitro susceptibility, tolerance and MLS resistance phenotypes of Group C and Group G streptococci isolated in Turkey between 1995 and 2002. Int J Antimicrob Agents. 2003;22:160–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Farrell DJ, Flamm RK, Sader HS, Jones RN. Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. Antimicrob Agents Chemother. 2014;58(7):3882–8.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Mendes RE, Flamm RK, Hogan PA, Ross JE, Jones RN. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States. Antimicrob Agents Chemother. 2014;58(2):1243–7.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Sader HS, Jones RN, Stilwell MG, Flamm RK. Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008–2011). Int J Antimicrob Agents. 2014;43(3):284–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother. 1995;39:577–85.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 1996;40:1817–24.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Pihlajamaki M, Kataja J, Seppala H, Elliot J, Leinonen M, Huovinen P, Jalava J. Ribosomal mutations in Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother. 2002;46:654–8.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Arpin C, Canron M-H, Maugein J, Quentin C. Incidence of mefA and mefE genes in viridans group streptococci. Antimicrob Agents Chemother. 1999;43:2335–6.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Seppälä H, Haanperä M, Al-Juhaish M, Järvinen H, Jalava J, Huovinen P. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J Antimicrob Chemother. 2003;52:636–44.PubMedCrossRefGoogle Scholar
  37. 37.
    Ioannidou S, Papaparaskevas J, Tassios PT, Foustoukou M, Legakis NJ, Vatopoulos AC. Prevalence and characterization of the mechanisms of macrolide, lincosamide and streptogramin resistance in viridans group streptococci. Int J Antimicrob Agents. 2003;22:626–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Gershon AS, de Azavedo JC, McGeer A, Ostrowska KI, Church D, Hoban DJ, Harding GK, Weiss K, Abbott L, Smaill F, Gourdeau M, Murray G, Low DE. Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000. Antimicrob Agents Chemother. 2002;46:1553–6.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Ergin A, Eser OK, Hascelik G. Erythromycin and penicillin resistance mechanisms among viridans group streptococci isolated from blood cultures of adult patients with underlying diseases. New Microbiol. 2011;34(2):187–93.PubMedGoogle Scholar
  40. 40.
    Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34:482–92.PubMedCrossRefGoogle Scholar
  41. 41.
    Matsui N, Ito M, Kuramae H, Inukai T, Sakai A, Okugawa M. Infective endocarditis caused by multidrug-resistant Streptococcus mitis in a combined immunocompromised patient: an autopsy case report. J Infect Chemother. 2013;19(2):321–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Liu M, Douthwaite S. Activity of the ketolide telithromycin is refractory to Erm monomethylation of bacterial rRNA. Antimicrob Agents Chemother. 2002;46:1629–33.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Jalava J, Kataja J, Seppala H, Huovinen P. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob Agents Chemother. 2001;45:789–93.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother. 1996;40:891–4.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Fluit AC, Schmitz FJ, Verhoef J, Milatovic D. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Int J Antimicrob Agents. 2004;24:59–66.PubMedCrossRefGoogle Scholar
  46. 46.
    Thal LA, Zervos MJ. Occurrence and epidemiology of resistance to virginiamycin and streptogramins. J Antimicrob Chemother. 1999;43:171–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Alcaide F, Carratala J, Linares J, Gudiol F, Martin R. In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrob Agents Chemother. 1996;40:2117–20.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Malbruny B, Canu A, Bozdogan B, Fantin B, Zarrouk V, Dutka-Malen S, Feger C, Leclercq R. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother. 2002;46:2200–7.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Kern W, Kurrle E. Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia. Infection. 1991;19:73–80.PubMedCrossRefGoogle Scholar
  50. 50.
    Ferrándiz MJ, Oteo J, Aracil B, Gómez-Garcés JL, De La Campa AG. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci. Antimicrob Agents Chemother. 1999;43:2520–3.PubMedPubMedCentralGoogle Scholar
  51. 51.
    González I, Georgiou M, Alcaide F, Balas D, Liñares J, de la Campa AG. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother. 1998;42:2792–8.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Guerin F, Varon E, Hoï AB, Gutmann L, Podglajen I. Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci. Antimicrob Agents Chemother. 2000;44:2197–200.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Ferrándiz MJ, Fenoll A, Liñares J, De La Campa AG. Horizontal Transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2000;44:840–7.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Balsalobre L, Ferrándiz MJ, Liñares J, Tubau F, de la Campa AG. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob Agents Chemother. 2003;47:2072–81.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Janoir C, Podglajen I, Kitzis MD, Poyart C, Gutmann L. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. J Infect Dis. 1999;180:555–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Marron A, Carratalà J, González-Barca E, Fernández-Sevilla A, Alcaide F, Gudiol F. Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer. Clin Infect Dis. 2000;31:1126–30.PubMedCrossRefGoogle Scholar
  57. 57.
    Aracil B, Minambres M, Oteo J, Alos J. High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J Antimicrob Chemother. 2001;48:592–4.PubMedCrossRefGoogle Scholar
  58. 58.
    Pfaller MA, Jones RN, Marshall SA, Edmond MB, Wenzel RP. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. Diagn Microbiol Infect Dis. 1997;29:259–63.PubMedCrossRefGoogle Scholar
  59. 59.
    Teng L-J, Hsueh P-R, Chen Y-C, Ho S-W, Luh K-T. Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis. J Antimicrob Chemother. 1998;41:621–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Renneberg J, Niemann LL, Gutschik E. Antimicrobial susceptibility of 278 streptococcal blood isolates to seven antimicrobial agents. J Antimicrob Chemother. 1997;39:135–40.PubMedCrossRefGoogle Scholar
  61. 61.
    Johnson AP, Warner M, Broughton K, James D, Efsratiou A, George RC, Livermore DM. Antibiotic susceptibility of streptococci and related genera causing endocarditis: analysis of UK reference laboratory referrals, January 1996 to March 2000. Br Med J. 2001;322:395–6.CrossRefGoogle Scholar
  62. 62.
    Reinert RR, von Eiff C, Kresken M, Brauers J, Hafner D, Al-Lahham A, Schorn H, Lutticken R, Peters G. Nationwide German multicenter study on the prevalence of antibiotic resistance in streptococcal blood isolates from neutropenic patients and comparative in vitro activities of quinupristin-dalfopristin and eight other antibiotics. J Clin Microbiol. 2001;39:1928–31.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Mendes RE, Sader HS, Flamm RK, Jones RN. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. J Antimicrob Chemother. 2014;69(6):1579–81.PubMedCrossRefGoogle Scholar
  64. 64.
    Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75(3):304–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Phillips I, Shannon KP. Aminoglycosides and aminocyclitols. In: O’Grady F, Lambert HP, Finch RG, Greenwood D, editors. Antibiotic and Chemotherapy: anti-infective agents and their use in therapy Seventh edit. New York: Churchill Livingstone Inc.; 1997. p. 164–201.Google Scholar
  66. 66.
    Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, Soler-Soler J, Thiene G, von Graevenitz A, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernandez Burgos E, Lekakis J, Lindahl B, Mazzotta G, Morais J, Smiseth OA, Vahanian A, Delahaye F, Parkhomenko A, Filipatos G, Aldershvile J, Vardas P, The Task Force on Infective Endocarditis of the European Society of Cardiology. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary. Eur Heart J. 2004;25:267–76.PubMedCrossRefGoogle Scholar
  67. 67.
    Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1995;39:445–52.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Ioannidou S, Tassios PT, Kotsovili-Tseleni A, Foustoukou M, Legakis NJ, Vatopoulos A. Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children. Int J Antimicrob Agents. 2001;17:195–201.PubMedCrossRefGoogle Scholar
  69. 69.
    Potgieter E, Carmichael M, Koornhof HJ, Chalkey LJ. In vitro antimicrobial susceptibility of viridans streptococci isolated from blood cultures. Eur J Clin Microb Infect Dis. 1992;11:543–6.CrossRefGoogle Scholar
  70. 70.
    Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003;36:473–81.PubMedCrossRefGoogle Scholar
  71. 71.
    Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159–68.PubMedCrossRefGoogle Scholar
  72. 72.
    Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother. 2013;57(2):1077–81.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagn Microbiol Infect Dis. 2013;76(2):206–13.PubMedCrossRefGoogle Scholar
  74. 74.
    Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56(9):4608–13.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Garcia-de-la-Maria C, Pericas JM, Del Rio A, Castaneda X, Vila-Farres X, Armero Y, Espinal PA, Cervera C, Soy D, Falces C, Ninot S, Almela M, Mestres CA, Gatell JM, Vila J, Moreno A, Marco F, Miro JM, Hospital Clinic Experimental Endocarditis Study Group. Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin. Antimicrob Agents Chemother. 2013;57(5):2319–25.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Lowbury EJ, Hurst L. The sensitivity of staphylococci and other wound bacteria to erythromycin, oleandomycin, and spiramycin. J Clin Pathol. 1959;12:163–9.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Kohn J, Evans AJ. Group A streptococci resistant to clindamycin. Br Med J. 1970;2:423.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Betriu C, Sanchez A, Gomez M, Cruceyra A, Picazo JJ. Antibiotic susceptibility of group A streptococci: a 6-year follow-up study. Antimicrob Agents Chemother. 1993;37:1717–9.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Seppälä H, Nissinen A, Järvinen H, Huovinen S, Henriksson T, Herva E, Holm SE, Jahkola M, Katila ML, Klaukka T, et al. Resistance to erythromycin in group A streptococci. N Engl J Med. 1992;326:292–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Seppälä H, Nissinen A, Yu Q, Huovinen P. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother. 1993;32:885–91.PubMedCrossRefGoogle Scholar
  81. 81.
    Seppälä H. Streptococcus pyogenes: erythromycin resistance and molecular typing. Turku University; 1994.Google Scholar
  82. 82.
    Mitsuhashi S, Inoue M, Saito K, Nakae M. Drug resistance in Streptococcus pyogenes strains isolated in Japan. In: Microbiology. Washington, DC: American Society for Microbiology; 1982. p. 151–4.Google Scholar
  83. 83.
    Stingemore N, Francis GRJ, Toohey M, McGechie DB. The emergence of erythromycin resistance in Streptococcus pyogenes in Fremantle, Western Australia. Med J Aust. 1989;150:626–7.PubMedGoogle Scholar
  84. 84.
    Phillips G, Parratt D, Orange GV, Harper I, McEwan H, Young N. Erythromycin-resistant Streptococcus pyogenes. J Antimicrob Chemother. 1990;25:723–4.PubMedCrossRefGoogle Scholar
  85. 85.
    Eickhoff TC, Klein JO, Daly AK, Ingall D, Finland M. Neonatal sepsis and other infections due to group B beta-hemolytic streptococci. N Engl J Med. 1964;271:1221–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Betriu C, Culebras E, Gomez M, Rodriguez-Avial I, Sanchez BA, Agreda MC, Picazo JJ. Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae. Antimicrob Agents Chemother. 2003;47:1112–4.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Hsueh PR, Teng LJ, Lee LN, Ho SW, Yang PC, Luh KT. High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan. Antimicrob Agents Chemother. 2001;45:3205–8.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    De Mouy D, Cavallo JD, Leclercq R, Fabre R. Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French multicenter study. Antimicrob Agents Chemother. 2001;45:2400–2.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Fitoussi F, Loukil C, Gros I, Clermont O, Mariani P, Bonacorsi S, Le Thomas I, Deforche D, Bingen E. Mechanisms of macrolide resistance in clinical group B streptococci isolated in France. Antimicrob Agents Chemother. 2001;45:1889–91.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Poyart C, Jardy L, Quesne G, Berche P, Trieu-Cuot P. Genetic basis of antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital. Antimicrob Agents Chemother. 2003;47:794–7.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Andrews JI, Diekema DJ, Hunter SK, Rhomberg PR, Pfaller MA, Jones RN, Doern GV. Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. Am J Obstet Gynecol. 2000;183:859–62.PubMedCrossRefGoogle Scholar
  92. 92.
    de Azavedo JC, McGavin M, Duncan C, Low DE, McGeer A. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob Agents Chemother. 2001;45:3504–8.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Uh Y, Jang IH, Hwang GY, Yoon KJ, Song W. Emerging erythromycin resistance among group B streptococci in Korea. Eur J Clin Microbiol Infect Dis. 2001;20:52–4.PubMedGoogle Scholar
  94. 94.
    Acikgoz ZC, Almayanlar E, Gamberzade S, Gocer S. Macrolide resistance determinants of invasive and noninvasive group B streptococci in a Turkish hospital. Antimicrob Agents Chemother. 2004;48:1410–2.PubMedCrossRefGoogle Scholar
  95. 95.
    Kataja J, Seppala H, Skurnik M, Sarkkinen H, Huovinen P. Different erythromycin resistance mechanisms in group C and group G streptococci. Antimicrob Agents Chemother. 1998;42:1493–4.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Wu JJ, Lin KY, Hsueh PR, Liu JW, Pan HI, Sheu SM. High incidence of erythromycin-resistant streptococci in Taiwan. Antimicrob Agents Chemother. 1997;41:844–6.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Chabbert YA. Antagonisme in vitro entre l’erythromycine et la spiramycine. Ann Inst Pasteur. 1956;90:787–90.Google Scholar
  98. 98.
    Hyder SL, Streitfeld MM. Inducible and constitutive resistance to macrolide antibiotics and lincomycin in clinically isolated strains of Streptococcus pyogenes. Antimicrob Agents Chemother. 1973;4:327–31.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Dixon JM, Lipinski AE. Infections with beta-Hemolytic Streptococcus resistant to lincomycin and erythromycin and observations on zonal-pattern resistance to lincomycin. J Infect Dis. 1974;130:351–6.PubMedCrossRefGoogle Scholar
  100. 100.
    Horodniceanu T, Bougueleret L, El-Solh N, Bouanchaud DH, Chabbert YA. Conjugative R plasmids in Streptococcus agalactiae (group B). Plasmid. 1979;2:197–206.PubMedCrossRefGoogle Scholar
  101. 101.
    Weisblum B, Holder SB, Halling SM. Deoxyribonucleic acid sequence common to staphylococcal and streptococcal plasmids which specify erythromycin resistance. J Bacteriol. 1979;138:990–8.PubMedPubMedCentralGoogle Scholar
  102. 102.
    Horinouchi S, Byeon WH, Weisblum B. A complex attenuator regulates inducible resistance to macrolides, lincosamides, and streptogramin type B antibiotics in Streptococcus sanguis. J Bacteriol. 1983;154:1252–62.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Shaw JH, Clewell DB. Complete nucleotide sequence of macrolide-lincosamide-streptogramin B-resistance transposon Tn917 in Streptococcus faecalis. J Bacteriol. 1985;164:782–96.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Seppälä H, Skurnik M, Soini H, Roberts MC, Huovinen P. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob Agents Chemother. 1998;42:257–62.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother. 1999;43:2823–30.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Fines M, Gueudin M, Ramon A, Leclercq R. In vitro selection of resistance to clindamycin related to alterations in the attenuator of the erm(TR) gene of Streptococcus pyogenes UCN1 inducibly resistant to erythromycin. J Antimicrob Chemother. 2001;48:411–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Clancy J, Petitpas J, Dib-Hajj F, Yuan W, Cronan M, Kamath AV, Bergeron J, Retsema JA. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol Microbiol. 1996;22:867–79.PubMedCrossRefGoogle Scholar
  108. 108.
    Portillo A, Lantero M, Gastanares MJ, Ruiz-Larrea F, Torres C. Macrolide resistance phenotypes and mechanisms of resistance in Streptococcus pyogenes in La Rioja, Spain. Int J Antimicrob Agents. 1999;13:137–40.PubMedCrossRefGoogle Scholar
  109. 109.
    Betriu C, Redondo M, Palau ML, Sanchez A, Gomez M, Culebras E, Boloix A, Picazo JJ. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci. Antimicrob Agents Chemother. 2000;44:1838–41.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Sauermann R, Gattringer R, Graninger W, Buxbaum A, Georgopoulos A. Phenotypes of macrolide resistance of group A streptococci isolated from outpatients in Bavaria and susceptibility to 16 antibiotics. J Antimicrob Chemother. 2003;51:53–7.PubMedCrossRefGoogle Scholar
  111. 111.
    Petinaki E, Kontos F, Pratti A, Skulakis C, Maniatis AN. Clinical isolates of macrolide-resistant Streptococcus pyogenes in Central Greece. Int J Antimicrob Agents. 2003;21:67–70.PubMedCrossRefGoogle Scholar
  112. 112.
    Kataja J, Huovinen P, Muotiala A, Vuopio-Varkila J, Efstratiou A, Hallas G, Seppala H, Finnish Study Group for Antimicrobial Resistance. Clonal spread of group A streptococcus with the new type of erythromycin resistance. J Infect Dis. 1998;177:786–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Yan JJ, Wu HM, Huang AH, Fu HM, Lee CT, Wu JJ. Prevalence of polyclonal mefA-containing isolates among erythromycin-resistant group A streptococci in Southern Taiwan. J Clin Microbiol. 2000;38:2475–9.PubMedPubMedCentralGoogle Scholar
  114. 114.
    Green M, Martin JM, Barbadora KA, Beall B, Wald ER. Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania. Antimicrob Agents Chemother. 2004;48:473–6.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Palavecino EL, Riedel I, Berrios X, Bajaksouzian S, Johnson D, Kaplan E, Jacobs MR. Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Santiago, Chile. Antimicrob Agents Chemother. 2001;45:339–41.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Martinez S, Amoroso AM, Famiglietti A, de Mier C, Vay C, Gutkind GO. Genetic and phenotypic characterization of resistance to macrolides in Streptococcus pyogenes from Argentina. Int J Antimicrob Agents. 2004;23:95–8.PubMedCrossRefGoogle Scholar
  117. 117.
    Kozlov RS, Bogdanovitch TM, Appelbaum PC, Ednie L, Stratchounski LS, Jacobs MR, Bozdogan B. Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia. Antimicrob Agents Chemother. 2002;46:2963–8.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Bozdogan B, Appelbaum PC. Macrolide resistance in Streptococci and Haemophilus influenzae. Clin Lab Med. 2004;24:455–75.PubMedCrossRefGoogle Scholar
  119. 119.
    Diekema DJ, Andrews JI, Huynh H, Rhomberg PR, Doktor SR, Beyer J, Shortridge VD, Flamm RK, Jones RN, Pfaller MA. Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. J Clin Microbiol. 2003;41:2659–61.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Poyart C, Quesne G, Acar P, Berche P, Trieu-Cuot P. Characterization of the Tn916-like transposon Tn3872 in a strain of abiotrophia defectiva (Streptococcus defectivus) causing sequential episodes of endocarditis in a child. Antimicrob Agents Chemother. 2000;44:790–3.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Betriu C, Culebras E, Rodriguez-Avial I, Gomez M, Sanchez BA, Picazo JJ. In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob Agents Chemother. 2004;48:323–5.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Bingen E, Leclercq R, Fitoussi F, Brahimi N, Malbruny B, Deforche D, Cohen R. Emergence of group A streptococcus strains with different mechanisms of macrolide resistance. Antimicrob Agents Chemother. 2002;46:1199–203.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Malbruny B, Nagai K, Coquemont M, Bozdogan B, Andrasevic AT, Hupkova H, Leclercq R, Appelbaum PC. Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. J Antimicrob Chemother. 2002;49:935–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Jalava J, Vaara M, Huovinen P. Mutation at the position 2058 of the 23S rRNA as a cause of macrolide resistance in Streptococcus pyogenes. Ann Clin Microbiol Antimicrob. 2004;3:5.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Giovanetti E, Brenciani A, Burioni R, Varaldo PE. A novel efflux system in inducibly erythromycin-resistant strains of Streptococcus pyogenes. Antimicrob Agents Chemother. 2002;46:3750–5.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Portillo A, Lantero M, Olarte I, Ruiz-Larrea F, Torres C. MLS resistance phenotypes and mechanisms in beta-haemolytic group B, C and G Streptococcus isolates in La Rioja, Spain. J Antimicrob Chemother. 2001;47:115–6.PubMedCrossRefGoogle Scholar
  127. 127.
    Culebras E, Rodriguez-Avial I, Betriu C, Redondo M, Picazo JJ. Macrolide and tetracycline resistance and molecular relationships of clinical strains of Streptococcus agalactiae. Antimicrob Agents Chemother. 2002;46:1574–6.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Bingen E, Fitoussi F, Doit C, Cohen R, Tanna A, George R, Loukil C, Brahimi N, Le Thomas I, Deforche D. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob Agents Chemother. 2000;44:1453–7.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Giovanetti E, Montanari MP, Mingoia M, Varaldo PE. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducible resistant strains. Antimicrob Agents Chemother. 1999;43:1935–40.PubMedPubMedCentralGoogle Scholar
  130. 130.
    Buu-Hoi A, Bieth G, Horaud T. Broad host range of streptococcal macrolide resistance plasmids. Antimicrob Agents Chemother. 1984;25:289–91.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Malke H. Transfer of a plasmid mediating antibiotic resistance between strains of Streptococcus pyogenes in mixed cultures. Z Allg Mikrobiol. 1975;15:645–9.PubMedCrossRefGoogle Scholar
  132. 132.
    Malke H, Starke R, Kohler W, Kolesnichenko G, Totolian AA. Bacteriophage P13234mo-mediated intra- and intergroup transduction of antibiotic resistance among streptococci. Zentralbl Bakteriol [Orig A]. 1975;233:24–34.Google Scholar
  133. 133.
    Horaud T, De Cespedes G, Clermont D, David F, Delbos F. Variability of chromosomal genetic elements in streptococci. In: Dunny GM, Cleary PP, McKay LL, editors. Genetics and molecular biology of streptococci, lactococci, and enterococci. Washington, DC: American Society for Microbiology; 1991. p. 16–20.Google Scholar
  134. 134.
    Kataja J, Huovinen P, Skurnik M, Seppala H. Erythromycin resistance genes in group A streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance. Antimicrob Agents Chemother. 1999;43:48–52.PubMedPubMedCentralGoogle Scholar
  135. 135.
    Giovanetti E, Magi G, Brenciani A, Spinaci C, Lupidi R, Facinelli B, Varaldo PE. Conjugative transfer of the erm(A) gene from erythromycin-resistant Streptococcus pyogenes to macrolide-susceptible S. pyogenes, Enterococcus faecalis and Listeria innocua. J Antimicrob Chemother. 2002;50:249–52.PubMedCrossRefGoogle Scholar
  136. 136.
    Le Bouguenec C, de Cespedes G, Horaud T. Molecular analysis of a composite chromosomal conjugative element (Tn3701) of Streptococcus pyogenes. J Bacteriol. 1988;170:3930–6.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Giovanetti E, Brenciani A, Lupidi R, Roberts MC, Varaldo PE. Presence of the tet(O) gene in erythromycin- and tetracycline-resistant strains of Streptococcus pyogenes and linkage with either the mef(A) or the erm(A) gene. Antimicrob Agents Chemother. 2003;47:2844–9.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Cresti S, Lattanzi M, Zanchi A, Montagnani F, Pollini S, Cellesi C, Rossolini GM. Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance. Antimicrob Agents Chemother. 2002;46:1816–22.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Banks DJ, Porcella SF, Barbian KD, Martin JM, Musser JM. Structure and distribution of an unusual chimeric genetic element encoding macrolide resistance in phylogenetically diverse clones of group A Streptococcus. J Infect Dis. 2003;188:1898–908.PubMedCrossRefGoogle Scholar
  140. 140.
    Kataja J, Huovinen P, Efstratiou A, Perez-Trallero E, Seppala H. Clonal relationships among isolates of erythromycin-resistant Streptococcus pyogenes of different geographical origin. Eur J Clin Microbiol Infect Dis. 2002;21:589–95.PubMedCrossRefGoogle Scholar
  141. 141.
    Reinert RR, Lutticken R, Sutcliffe JA, Tait-Kamradt A, Cil MY, Schorn HM, Bryskier A, Al-Lahham A. Clonal relatedness of erythromycin-resistant Streptococcus pyogenes isolates in Germany. Antimicrob Agents Chemother. 2004;48:1369–73.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Katz KC, McGeer AJ, Duncan CL, Ashi-Sulaiman A, Willey BM, Sarabia A, McCann J, Pong-Porter S, Rzayev Y, de Azavedo JS, Low DE. Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001. Antimicrob Agents Chemother. 2003;47:2370–2.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group S streptococci in schoolchildren in Pittsburgh. N Engl J Med. 2002;346:1200–6.PubMedCrossRefGoogle Scholar
  144. 144.
    Perez-Trallero E, Marimon JM, Montes M, Orden B, de Pablos M. Clonal differences among erythromycin-resistant streptococcus pyogenes in Spain. Emerg Infect Dis. 1999;5:235–40.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Reig M, Galan J, Baquero F, Perez-Diaz JC. Macrolide resistance in Peptostreptococcus spp. mediated by ermTR: possible source of macrolide-lincosamide-streptogramin B resistance in Streptococcus pyogenes. Antimicrob Agents Chemother. 2001;45:630–2.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Granizo JJ, Aguilar L, Casal J, Dal-Re R, Baquero F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986–1997). J Antimicrob Chemother. 2000;46:959–64.PubMedCrossRefGoogle Scholar
  147. 147.
    Seppälä H, Klaukka T, Lehtonen R, Nenonen E, Huovinen P. Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci. Clin Infect Dis. 1995;21:1378–85.PubMedCrossRefGoogle Scholar
  148. 148.
    Bergman M, Huikko S, Pihlajamaki M, Laippala P, Palva E, Huovinen P, Seppala H. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997–2001. Clin Infect Dis. 2004;38:1251–6.PubMedCrossRefGoogle Scholar
  149. 149.
    Ko WC, Lee HC, Wang LR, Lee CT, Liu AJ, Wu JJ. Serotyping and antimicrobial susceptibility of group B Streptococcus over an eight-year period in southern Taiwan. Eur J Clin Microbiol Infect Dis. 2001;20:334–9.PubMedGoogle Scholar
  150. 150.
    Bowling JE, Owens AE, McElmeel ML, Fulcher LC, Herrera ML, Wickes BL, Jorgensen JH. Detection of inducible clindamycin resistance in beta-hemolytic streptococci by using the CLSI broth microdilution test and erythromycin-clindamycin combinations. J Clin Microbiol. 2010;48(6):2275–7.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Lewis 2nd JS, Lepak AJ, Thompson 3rd GR, Craig WA, Andes DR, Sabol-Dzintars KE, Jorgensen JH. Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections. Antimicrob Agents Chemother. 2014;58(3):1327–31.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Richter SS, Heilmann KP, Dohrn CL, Beekmann SE, Riahi F, Garcia-de-Lomas J, Ferech M, Goossens H, Doern GV. Increasing telithromycin resistance among Streptococcus pyogenes in Europe. J Antimicrob Chemother. 2008;61(3):603–11.PubMedCrossRefGoogle Scholar
  153. 153.
    Sexton DJ. Antimicrobial therapy of native valve endocarditis. In: Post TW, editor. UpToDate. Waltham, MA: UpToDate. Accessed 14 Sept 2014.Google Scholar
  154. 154.
    Hogevik H, Olaison L, Andersson R, Lindberg J, Alestig K. Epidemiologic aspects of infective endocarditis in an urban population: a 5-year prospective study. Medicine (Baltimore). 1995;74:324–39.CrossRefGoogle Scholar
  155. 155.
    Watanakunakorn C, Burkert T. Infective endocarditis at a large community teaching hospital, 1980–1990. A review of 210 episodes. Medicine (Baltimore). 1993;72:90–102.CrossRefGoogle Scholar
  156. 156.
    Eykyn SJ. Bacteraemia, septicaemia and endocarditis, Vol. Chapter 16. p. 277–98. 1999Google Scholar
  157. 157.
    Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med. 2001;345:1318–30.PubMedCrossRefGoogle Scholar
  158. 158.
    Alestig K, Hogevik H, Olaison L. Infective endocarditis: a diagnostic and therapeutic challenge for the new millennium. Scand J Infect Dis. 2000;32:343–56.PubMedCrossRefGoogle Scholar
  159. 159.
    Castillo JC, Anguita MP, Ruiz M, Peña L, Santisteban M, Puentes M, Arizón JM, Suárez de Lezo J. [Changing epidemiology of native valve infective endocarditis]. Rev Esp Cardiol. 2011;64(7):594–8.PubMedCrossRefGoogle Scholar
  160. 160.
    Gutschik E. New developments in the treatment of infective endocarditis infective cardiovasculitis. Int J Antimicrob Agents. 1999;13:79–92.PubMedCrossRefGoogle Scholar
  161. 161.
    Shanson DC. New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. J Antimicrob Chemother. 1998;42:292–6.PubMedCrossRefGoogle Scholar
  162. 162.
    Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(23):e394–434.Google Scholar
  163. 163.
    Levitz RE. Prosthetic-valve endocarditis caused by penicillin-resistant Streptococcus mitis. N Engl J Med. 1999;340:1843–4.PubMedCrossRefGoogle Scholar
  164. 164.
    Sabella C, Murphy D, Drummond-Webb J. Endocarditis due to Streptococcus mitis with high-level resistance to penicillin and ceftriaxone. J Am Med Assoc. 2001;285:2195.CrossRefGoogle Scholar
  165. 165.
    Lonks JR, Dickinson BP, Runarsdottir V. Endocarditis due to Streptococcus mitis with high-level resistance to penicillin and cefotaxime. N Engl J Med. 1999;341:1239.PubMedCrossRefGoogle Scholar
  166. 166.
    Levy CS, Kogulan P, Gill VJ, Croxton MB, Kane JG, Lucey DR. Endocarditis Caused by Penicillin-Resistant Viridans Streptococci: 2 Cases and Controversies in Therapy. Clin Infect Dis. 2001;33:577–9.PubMedCrossRefGoogle Scholar
  167. 167.
    Hamza N, Ortiz J, Bonomo RA. Isolated pulmonic valve infective endocarditis: a persistent challenge. Infection. 2004;32:170–5.PubMedCrossRefGoogle Scholar
  168. 168.
    Dinani A, Ktaich N, Urban C, Rubin D. Levofloxacin-resistant-Streptococcus mitis endophthalmitis: a unique presentation of bacterial endocarditis. J Med Microbiol. 2009;58(Pt 10):1385–7.PubMedCrossRefGoogle Scholar
  169. 169.
    Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). In: Post TW, editor. UpToDate. Waltham, MA: UpToDate. Accessed 14 Sept 2014.Google Scholar
  170. 170.
    Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother. 1998;41 Suppl 4:13–24.PubMedCrossRefGoogle Scholar
  171. 171.
    Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33:947–53.PubMedCrossRefGoogle Scholar
  172. 172.
    Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004;39:S25–31.PubMedCrossRefGoogle Scholar
  173. 173.
    Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25:247–59.PubMedCrossRefGoogle Scholar
  174. 174.
    Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14:1201–7.PubMedCrossRefGoogle Scholar
  175. 175.
    Picazo J. Management of the febrile neutropenic patient: a consensus conference. Clin Infect Dis. 2004;39:S1–6.PubMedCrossRefGoogle Scholar
  176. 176.
    Marín M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratalà J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore). 2014;93(3):143–9.CrossRefGoogle Scholar
  177. 177.
    Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis. 2004;39:S7–10.PubMedCrossRefGoogle Scholar
  178. 178.
    Gonzalez-Barca E, Fernández-Sevilla A, Carratalà J, Grañena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis. 1996;15:291–6.PubMedCrossRefGoogle Scholar
  179. 179.
    Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med. 1994;97:256–64.PubMedCrossRefGoogle Scholar
  180. 180.
    Alcaide F, Liñares J, Pallares R, Carratalà J, Benitez MA, Gudiol F, Martin R. In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother. 1995;39:2243–7.PubMedPubMedCentralCrossRefGoogle Scholar
  181. 181.
    Villablanca J, Steiner M, Kersey J, Ramsay NKC, Ferrieri P, Haake R, Weisdorf D. The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant. 1990;6:387–93.Google Scholar
  182. 182.
    Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18:25–31.PubMedCrossRefGoogle Scholar
  183. 183.
    Wisplinghoff H, Reinert RR, Cornely O, Seifert H. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J Clin Microbiol. 1999;37:1876–80.PubMedPubMedCentralGoogle Scholar
  184. 184.
    Richard P, Amador Del Valle G, Moreau P, Milpied N, Felice MP, Daeschler T, Harousseau JL, Richet H. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet. 1995;345:1607–9.PubMedCrossRefGoogle Scholar
  185. 185.
    Kern W, Kurrle E, Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection. 1990;18:138–45.PubMedCrossRefGoogle Scholar
  186. 186.
    Steiner M, Villablanca J, Kersey J, Ramsay N, Haake R, Ferrieri P, Weisdorf D. Viridans streptococcal shock in bone marrow transplantation patients. Am J Hematol. 1993;42:354–8.PubMedCrossRefGoogle Scholar
  187. 187.
    Zinner S, Calandra T, Meunier F, Gaya H, Viscoli C, Klastersky J, Glauser MP, Langenaken J, Paesmans M. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. J Am Med Assoc. 1994;272:1183–9.CrossRefGoogle Scholar
  188. 188.
    Han SB, Bae EY, Lee JW, Lee DG, Chung NG, Jeong DC, Cho B, Kang JH, Kim HK. Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children. BMC Infect Dis. 2013;13:273.PubMedPubMedCentralCrossRefGoogle Scholar
  189. 189.
    Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–93.PubMedCrossRefGoogle Scholar
  190. 190.
    Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37:382–9.PubMedCrossRefGoogle Scholar
  191. 191.
    Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF, Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.PubMedCrossRefGoogle Scholar
  192. 192.
    Garnica M, Nouér SA, Pellegrino FL, Moreira BM, Maiolino A, Nucci M. Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infect Dis. 2013;13(1):356.PubMedPubMedCentralCrossRefGoogle Scholar
  193. 193.
    Shelburne 3rd SA, Lasky RE, Sahasrabhojane P, Tarrand JT, Rolston KV. Development and validation of a clinical model to predict the presence of β-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients. Clin Infect Dis. 2014;59(2):223–30.PubMedCrossRefGoogle Scholar
  194. 194.
    Maeda Y, Elborn JS, Parkins MD, Reihill J, Goldsmith CE, Coulter WA, Mason C, Millar BC, Dooley JS, Lowery CJ, Ennis M, Rendall JC, Moore JE. Population structure and characterization of viridans group streptococci (VGS) including Streptococcus pneumoniae isolated from adult patients with cystic fibrosis (CF). J Cyst Fibros. 2011;10(2):133–9.PubMedCrossRefGoogle Scholar
  195. 195.
    Cooper RJ, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med. 2001;134(6):509–17.PubMedCrossRefGoogle Scholar
  196. 196.
    Varaldo PE, Debbia EA, Nicoletti G, Pavesio D, Ripa S, Schito GC, Tempera G, Artemis-Italy Study Group. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes. Clin Infect Dis. 1999;29:869–73.PubMedCrossRefGoogle Scholar
  197. 197.
    Rondini G, Cocuzza CE, Cianflone M, Lanzafame A, Santini L, Mattina R. Bacteriological and clinical efficacy of various antibiotics used in the treatment of streptococcal pharyngitis in Italy. An epidemiological study. Int J Antimicrob Agents. 2001;18:9–17.PubMedCrossRefGoogle Scholar
  198. 198.
    Bassetti M, Manno G, Collida A, Ferrando A, Gatti G, Ugolotti E, Cruciani M, Bassetti D. Erythromycin resistance in Streptococcus pyogenes in Italy. Emerg Infect Dis. 2000;6:180–3.PubMedPubMedCentralCrossRefGoogle Scholar
  199. 199.
    Chen I, Kaufisi P, Erdem G. Emergence of erythromycin- and clindamycin-resistant Streptococcus pyogenes emm 90 strains in Hawaii. J Clin Microbiol. 2011;49(1):439–41.PubMedCrossRefGoogle Scholar
  200. 200.
    Diekema DJ, Beach ML, Pfaller MA, Jones RN, SENTRY Participants Group. Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. Clin Microbiol Infect. 2001;7:152–7.PubMedCrossRefGoogle Scholar
  201. 201.
    Horn DL, Zabriskie JB, Austrian R, Cleary PP, Ferretti JJ, Fischetti VA, Gotschlich E, Kaplan EL, McCarty M, Opal SM, Roberts RB, Tomasz A, Wachtfogel Y. Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis. 1998;26:1341–5.PubMedCrossRefGoogle Scholar
  202. 202.
    Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, Huovinen P. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med. 1997;337:441–6.PubMedCrossRefGoogle Scholar
  203. 203.
    Fujita K, Murono K, Yoshikawa M, Murai T. Decline of erythromycin resistance of group A streptococci in Japan. Pediatr Infect Dis J. 1994;13:1075–8.PubMedCrossRefGoogle Scholar
  204. 204.
    Cizman M, Pokorn M, Seme K, Orazem A, Paragi M. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J Antimicrob Chemother. 2001;47:475–7.PubMedCrossRefGoogle Scholar
  205. 205.
    Commitee. Revised guidelines for prevention of early-onset group B streptococcal (GBS) infection. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 1997;99:489–96.CrossRefGoogle Scholar
  206. 206.
    Sunkara B, Bheemreddy S, Lorber B, Lephart PR, Hayakawa K, Sobel JD, Kaye KS, Marchaim D. Group B Streptococcus infections in non-pregnant adults: the role of immunosuppression. Int J Infect Dis. 2012;16(3):e182–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Nainee Desai
    • 1
  • Judith Steenbergen
    • 2
  • David E. Katz
    • 3
  1. 1.Medical Affairs DepartmentCubist PharmaceuticalsLexingtonUSA
  2. 2.Clinical Microbiology DepartmentCubist PharmaceuticalsLexingtonUSA
  3. 3.Internal Medicine Department ‘D’Shaare Zedek Medical Center, Hebrew University Hadassah Medical CenterJerusalemIsrael

Personalised recommendations